Bimatoprost
Lumigan · Latisse · Durysta
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Elevated intraocular pressure — open-angle glaucoma or ocular hypertension (Lumigan 0.01% or 0.03% ophthalmic solution) | Adults (pediatric use <16 years not recommended) | Monotherapy or adjunctive | FDA Approved |
| Elevated intraocular pressure — open-angle glaucoma or ocular hypertension (Durysta 10 mcg intracameral implant) | Adults; single implant per eye only | Monotherapy (single administration) | FDA Approved |
| Hypotrichosis of the eyelashes — to increase eyelash length, thickness, and darkness (Latisse 0.03% ophthalmic solution) | Adults | Monotherapy (topical eyelid application) | FDA Approved |
Bimatoprost was first approved by the FDA in 2001 as Lumigan for reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. In 2008 the same molecule at 0.03% gained a cosmetic indication for eyelash hypotrichosis under the Latisse brand after clinicians observed eyelash lengthening as a consistent off-target effect during glaucoma treatment. In March 2020 the FDA approved Durysta, a biodegradable 10 mcg intracameral implant delivering sustained-release bimatoprost; it is indicated for single-use only because repeated implantation in pivotal trials was associated with corneal endothelial cell loss. In contemporary practice the topical solution remains a guideline-preferred first-line IOP-lowering agent, grouped alongside latanoprost and travoprost in the prostaglandin analog class.
Androgenetic alopecia and eyebrow hypotrichosis (topical bimatoprost 0.03%): small randomized trials suggest modest benefit for scalp hair growth and eyebrow density. Evidence: low quality.
Chemotherapy-induced madarosis: open-label data in post-chemotherapy patients support eyelash regrowth; included in an FDA-reviewed pediatric safety study but not a separate approved indication. Evidence: low to moderate quality.
Vitiligo repigmentation: case series and small comparative studies suggest induction of melanogenesis in depigmented skin when applied topically. Evidence: very low quality.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Open-angle glaucoma / ocular hypertension — newly diagnosed, monotherapy (Lumigan 0.03%) | 1 drop OU/OD/OS in the evening | 1 drop once daily in the evening | 1 drop once daily | Once-daily evening dosing only; more frequent dosing reduces efficacy. Expect ~7–8 mmHg reduction from baseline at peak. |
| Open-angle glaucoma / ocular hypertension — lower hyperemia profile preferred (Lumigan 0.01%) | 1 drop OU/OD/OS in the evening | 1 drop once daily in the evening | 1 drop once daily | IOP-lowering effect is slightly less than 0.03% (by ~0.5 mmHg) but with ~30% rather than ~45% hyperemia. Preferred for patients intolerant of 0.03% due to hyperemia. |
| Glaucoma with inadequate control on monotherapy — adjunctive use | 1 drop in the evening | 1 drop once daily in the evening | 1 drop once daily | Separate from other topical ophthalmic drops by at least 5 minutes. Can combine with beta-blockers, alpha-agonists, CAIs, or rho kinase inhibitors. |
| Glaucoma with non-adherence to topical drops — sustained delivery (Durysta implant) | 10 mcg intracameral implant ×1 | Single administration only | 1 implant per eye, lifetime | Duration of IOP control ~4–6 months; ~28% of patients control IOP for up to 24 months without rescue. Do not re-implant same eye (corneal endothelial cell loss risk). |
| Eyelash hypotrichosis — cosmetic (Latisse 0.03%) | 1 drop per upper eyelid nightly | 1 drop per upper eyelid nightly | 1 drop per lid nightly | Apply to upper lid margin using single-use sterile applicator; do NOT apply to lower lid. Onset ~2 months; full effect at 16 weeks; lashes return to baseline on discontinuation. |
Population-Specific Adjustments
| Population | Adjustment | Notes |
|---|---|---|
| Renal impairment | No adjustment required | Systemic exposure from topical dosing is negligible. |
| Hepatic impairment | No formal studies; no adjustment typically made | Bimatoprost is metabolised by oxidation and glucuronidation outside the CYP system. |
| Elderly (≥65 years) | No adjustment required | No overall differences in safety or efficacy observed. |
| Pediatric <16 years (Lumigan) | Not recommended | Long-term pigmentation concerns; Durysta not studied in children. |
| Pediatric (Latisse) | Safety evaluated in 16-week study; use on case-by-case basis | Studied in post-chemotherapy and alopecia areata; no new safety signals. |
| Pregnancy | Use only if potential benefit justifies potential fetal risk | Animal data showed abortion at high oral doses; no adequate human studies. |
Evening instillation is recommended because diurnal IOP peaks are typically lower and the patient is less likely to disrupt the film by rubbing or reapplying cosmetics. More-than-once-daily dosing paradoxically reduces IOP-lowering efficacy — a receptor desensitisation effect characteristic of prostaglandin analogs. When multiple topical agents are needed, instruct patients to space drops by at least 5 minutes to prevent washout, and to use punctal occlusion (gentle pressure over the medial canthus for 1–2 minutes) to reduce systemic absorption and local adverse events such as conjunctival hyperemia.
Pharmacology
Mechanism of Action
Bimatoprost is a synthetic prostamide — a structural analog of prostaglandin F2α and of the endogenous prostamides derived from anandamide — with potent ocular hypotensive activity. It lowers intraocular pressure predominantly by increasing aqueous humor outflow through both the trabecular (conventional) and uveoscleral (unconventional) pathways. Unlike classical prostaglandin analogs such as latanoprost and travoprost, bimatoprost shows only weak activity at the prostaglandin FP receptor in isolated preparations, leading to the hypothesis that it acts via a distinct “prostamide-sensitive” receptor; regardless of the molecular target, the net clinical effect is a 25–35% reduction in IOP with once-daily dosing. For eyelash hypotrichosis, bimatoprost is thought to prolong the anagen (growth) phase of the hair cycle and increase the proportion of hairs in active growth, along with stimulating follicular melanogenesis — effects mediated at local prostanoid receptors in the follicle.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Topical ocular; peak blood levels within 10 minutes; steady-state Cmax ~0.08 ng/mL; below detection within ~1.5 hours; steady-state reached within 1 week | Systemic exposure is minimal, explaining the favourable systemic safety profile; effectively no drug accumulation. |
| Distribution | Steady-state Vd 0.67 L/kg; ~88% plasma protein bound; resides primarily in plasma rather than erythrocytes | Distribution is limited; protein binding is not a source of significant drug-drug interaction concern at the low systemic exposures seen with ocular dosing. |
| Metabolism | Hepatic oxidation, N-deethylation, and glucuronidation; bimatoprost is the major circulating species (non-CYP-mediated) | Negligible risk of CYP-based drug interactions; no adjustment for hepatic enzyme inducers or inhibitors. |
| Elimination | Plasma half-life ~45 minutes after IV infusion; blood clearance 1.5 L/hr/kg; ~67% excreted in urine, ~25% in feces | Rapid systemic clearance; no dose adjustment needed for renal or hepatic impairment given negligible systemic exposure from topical dosing. |
Side Effects
The adverse event profile varies meaningfully across the three formulations. The 0.03% topical solution (Lumigan) has the highest incidence of conjunctival hyperemia; the 0.01% formulation (Lumigan 0.01%) has a lower hyperemia rate due to reduced preservative load; the intracameral implant (Durysta) avoids the classical “drops” side effects but introduces anterior segment risks related to the implant itself. Incidence figures below are drawn from the pivotal trials and FDA prescribing information for each product.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Conjunctival hyperemia (Lumigan 0.03%) | 25–45% | The signature side effect of the 0.03% formulation; typically mild, often improves over first weeks. |
| Conjunctival hyperemia (Lumigan 0.01%) | ~31% | Lower incidence than 0.03% in head-to-head 12-month trial; driver for choosing this formulation. |
| Conjunctival hyperemia (Durysta implant) | ~27% | Largely procedure-related; most cases occur within 2 days of implantation and resolve. |
| Eyelash growth / hypertrichosis (Lumigan 0.03%) | 15–45% | Increased length, thickness, and darkness of lashes in treated eye; reversible on discontinuation. |
| Ocular pruritus (Lumigan 0.03%) | >10% | Often mild; typically does not require treatment discontinuation. |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Pigmentation of periocular skin / eyelid darkening | 3–10% | Due to increased melanin content in melanocytes; usually reversible on discontinuation. |
| Ocular dryness, ocular burning, foreign body sensation | 3–10% | Often multifactorial; artificial tears between doses may help. |
| Blepharitis, periorbital erythema, eyelid pruritus | 1–10% | Lid hygiene and warm compresses typically adequate; re-examine for contact dermatitis if persistent. |
| Superficial punctate keratitis | 1–10% | Preservative-related in many cases; consider preservative-free formulation if tolerated. |
| Eye pain, visual disturbance, blurred vision | 1–10% | Usually transient after instillation; sustained blur warrants examination for other causes. |
| Iris hyperpigmentation | 1–3% (topical); ~3% (implant trials) | Gradual; spreads centrifugally from pupil; considered permanent; counsel before initiation. |
| Eye pain and photophobia (Durysta) | 5–10% | Largely procedure-related; evaluate any progressive symptoms to exclude endophthalmitis. |
| Corneal endothelial cell loss (Durysta) | 5–10% | Key reason for single-implant restriction; screen corneal endothelial cell density before offering. |
| Iritis / anterior chamber cell (Durysta) | 5–10% | Usually mild; topical corticosteroids if clinically significant. |
| Eye pruritus & skin hyperpigmentation (Latisse) | ~3–4% | Most frequent Latisse adverse events; skin hyperpigmentation usually reversible. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Cystoid macular edema | Rare (~1–2% in at-risk eyes) | Weeks to months | OCT of macula; discontinue bimatoprost; treat with topical NSAID and/or corticosteroid |
| Anterior uveitis / iritis | <1% (topical); 5–10% (implant) | Days to weeks | Slit-lamp exam; topical corticosteroid; discontinue in recurrent/severe cases |
| Bacterial keratitis (from contaminated bottle) | Rare | Any time — often after contamination | Urgent ophthalmology referral; corneal scrapings and culture; targeted topical antibiotics |
| Endophthalmitis (Durysta only) | Very rare | Hours to days post-implantation | Emergency vitreoretinal referral; intravitreal antibiotics ± vitrectomy |
| Corneal decompensation (Durysta; more with repeated implants) | <1% after single implant | Months to years | Corneal imaging; specular microscopy; corneal transplant referral if progressive |
| Implant migration to posterior segment (Durysta) | Very rare | Immediately or within days | Vitreoretinal referral; may require surgical removal |
| Hypersensitivity / anaphylaxis | Very rare | Minutes to hours | Discontinue permanently; emergency management as indicated |
| Permanent iris darkening | 1–3% (long-term use) | Months to years | Counsel before initiation; does not require discontinuation but warrants regular monitoring |
| Prostaglandin-associated periorbitopathy (PAP) including deepening of upper eyelid sulcus, ptosis, orbital fat atrophy, enophthalmos | Up to 30–60% on long-term use (more in bimatoprost than other PGAs) | Typically after 1–2 years | Document with photographs; consider switch to latanoprost (less associated) or non-PGA class; largely reversible within ~15 months of discontinuation |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Conjunctival hyperemia | 0.5–3% | Most common cause across both concentrations; incidence ~1.6% for 0.01% vs ~3% for 0.03%. |
| Cosmetic concerns — periocular skin darkening, PAP, eyelash asymmetry | Not formally quantified | Increasingly cited in real-world discontinuation, particularly in patients treated unilaterally. |
| Ocular surface disease (burning, itching, dryness) | <2% | Preservative (benzalkonium chloride) frequently implicated; a preservative-free option may help. |
Iris hyperpigmentation is unique to the prostaglandin analog class and is considered permanent. The pigmentation results from increased melanin production within existing stromal melanocytes rather than proliferation, and typically spreads concentrically from the pupillary margin. Counsel every patient before initiation, particularly those with mixed-colour (hazel, green, blue-brown) irides who are at greatest risk. Document baseline iris colour with photographs, warn about the possibility of asymmetric change in unilateral treatment, and re-examine at least annually. Iris darkening alone does not require discontinuation but should trigger a conversation about alternatives if cosmetic concerns outweigh IOP-lowering benefit.
Drug Interactions
Because systemic absorption from ocular bimatoprost is negligible and the drug is metabolised outside the CYP system (via oxidation, N-deethylation, and glucuronidation), clinically significant systemic drug-drug interactions are not expected. The meaningful interactions are instead ocular or topical in nature — most notably interference between prostaglandin analogs and the issue of benzalkonium chloride (BAK) preservative binding to soft contact lenses.
Monitoring
-
Intraocular Pressure
Baseline, 4–6 weeks after initiation, then every 3–12 months based on stability
Routine Establish response after ~6 weeks; expect 7–8 mmHg drop from baseline with Lumigan 0.03%. Check more frequently in advanced disease or when stability is uncertain. -
Optic Nerve Head / RNFL
Every 6–12 months
Routine OCT imaging of peripapillary RNFL and macular ganglion cell complex. Document progression independent of IOP response. -
Visual Field
Every 6–12 months; more often if progressing
Routine Standard automated perimetry; compare serial studies using progression software. More frequent testing in advanced glaucoma. -
Iris Colour
Baseline photograph, then at each visit
Routine Document baseline colour and re-examine at least annually. Special attention in mixed-colour (hazel/green) irides with unilateral treatment. -
Periocular Tissue
Each visit — external examination and photographs if concern
Routine Look for upper lid sulcus deepening, ptosis, orbital fat atrophy (PAP), and skin hyperpigmentation. Switch class if cosmetic impact is problematic. -
Corneal Surface / Ocular Surface Disease
Annually and as symptoms arise
Routine Slit-lamp examination for superficial punctate keratitis, tear break-up time, and blepharitis; preservative burden is often the driver. -
Corneal Endothelial Cell Density (Durysta)
Before every implant; periodic thereafter
Routine Specular microscopy required; implant limited to single administration per eye because repeated dosing causes progressive endothelial cell loss. -
Macular OCT
If patient reports new vision change or risk factors
Trigger-based Rule out cystoid macular edema in aphakic/pseudophakic patients with a torn posterior capsule, uveitis, or new photopsia/blurred vision. -
Anterior Chamber Inflammation
Triggered by symptoms (pain, photophobia, redness)
Trigger-based Slit-lamp with careful iris and AC cell/flare assessment; particularly important in Durysta recipients with post-procedural symptoms. -
Adherence / Technique Check
Each visit
Routine Ask open-ended questions about missed doses. Observe instillation technique and reinforce punctal occlusion if tolerability or systemic concerns exist.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to bimatoprost or any excipient — applies to all formulations.
- Durysta only — Active or suspected ocular or periocular infection at time of implantation.
- Durysta only — Corneal endothelial cell dystrophy (e.g., Fuchs’ endothelial dystrophy) — unacceptable risk of corneal decompensation.
- Durysta only — Prior corneal transplantation or endothelial keratoplasty (e.g., DSAEK, DMEK) — graft failure risk.
- Durysta only — Absent or ruptured posterior lens capsule — risk of implant migration into the posterior segment.
Relative Contraindications (Specialist Input Recommended)
- Active intraocular inflammation (e.g., uveitis, iritis) — may be exacerbated; specialist-directed risk-benefit discussion, often with co-management.
- Risk factors for cystoid macular edema — aphakia, pseudophakia with torn posterior capsule, prior CME, history of uveitic macular edema. Document shared decision.
- Narrow iridocorneal angles (Shaffer grade <3) for Durysta — implant may not settle in the inferior angle.
- Limited corneal endothelial cell reserve for Durysta (CECD <2000 cells/mm² in some centres) — specialist evaluation before implantation.
- Pregnancy — use only when potential benefit outweighs potential fetal risk; shared decision and documentation.
Use with Caution
- Mixed-colour irides (hazel, green, or blue-brown) — highest risk of noticeable and permanent iris darkening; consent before initiation.
- Unilateral therapy — risk of cosmetic asymmetry in iris colour, periocular pigmentation, eyelash appearance, and PAP features; photograph at baseline.
- Soft contact lens wearers — remove lenses before instillation (benzalkonium chloride absorption); reinsert after 15 minutes.
- History of herpes simplex keratitis — case reports of reactivation with prostaglandin analogs.
- Lactation — use with caution; bimatoprost is present in animal milk and systemic absorption in infants is uncharacterized.
- Pediatric patients <16 years for Lumigan — long-term pigmentation concerns; Durysta not studied in children.
The FDA labelling for all bimatoprost products carries standardised warnings on changes to pigmented tissues: increased brown pigmentation of the iris is likely to be permanent, while eyelid and eyelash pigmentation and eyelash growth are generally reversible on discontinuation. Prostaglandin-associated periorbitopathy — including deepening of the upper eyelid sulcus, upper lid ptosis, orbital fat atrophy, and enophthalmos — has been reported as a postmarketing class effect, particularly with long-term use. Additional warnings apply to the intracameral implant (Durysta): single-administration-only restriction due to corneal endothelial cell loss with repeated implantation, and procedure-related risks including endophthalmitis.
Patient Counselling
Purpose of Therapy
Explain that bimatoprost lowers the pressure inside the eye by helping fluid drain out more effectively, which is essential to slow or prevent damage to the optic nerve from glaucoma. Emphasise that glaucoma rarely causes symptoms until vision has already been lost, so consistent daily use is the single most important factor in preserving eyesight — even though patients will not feel any improvement. For patients using Latisse, explain that it is a cosmetic prescription treatment that lengthens, thickens, and darkens eyelashes by prolonging the growth phase; lashes return to baseline when the product is stopped.
How to Take
For eye drops: instill one drop in the affected eye(s) once each evening. Remove contact lenses first and wait 15 minutes before reinserting them. If using multiple eye drops, wait at least five minutes between each one. Close the eye gently for one to two minutes after instillation and apply light pressure to the inner corner (near the nose) — this reduces systemic absorption and local side effects. Wash hands before and after use and never let the bottle tip touch the eye, eyelid, or any surface. For Latisse: apply only to the upper eyelid margin using the single-use sterile applicator provided, once every evening; never apply to the lower lid and never reuse applicators. Results begin at about 2 months, with full effect at 16 weeks.
Sources
- AbbVie Inc. LUMIGAN® (bimatoprost ophthalmic solution) 0.01% full prescribing information. 2024. https://www.rxabbvie.com/pdf/lumigan_pi.pdf Current FDA-approved label for the lower-strength topical glaucoma formulation — primary source for dosing, warnings, and adverse reaction data.
- AbbVie Inc. LATISSE® (bimatoprost ophthalmic solution) 0.03% full prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022369s014lbl.pdf FDA label for the eyelash hypotrichosis indication — source for cosmetic dosing, application technique, and eyelash-specific adverse event rates.
- AbbVie Inc. DURYSTA™ (bimatoprost intracameral implant) full prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211911s002lbl.pdf Current FDA label for the sustained-release intracameral implant — source for single-use restriction, corneal endothelial warnings, and implant-specific adverse events.
- Allergan. LUMIGAN® (bimatoprost ophthalmic solution) 0.03% prescribing information. Access Data FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021275s029lbl.pdf Historic FDA label for the 0.03% glaucoma formulation — referenced for original adverse event incidence data from pivotal trials.
- Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149(4):661–671.e1. https://doi.org/10.1016/j.ajo.2009.12.003 Pivotal head-to-head comparison establishing 0.01% as similarly effective with a markedly better tolerability profile than 0.03%.
- Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66(5):801–806. https://doi.org/10.1016/j.jaad.2011.06.005 Pivotal Latisse trial demonstrating increased eyelash prominence and defining the cosmetic adverse event profile.
- Medeiros FA, Walters TR, Kolko M, et al; ARTEMIS 1 Study Group. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. https://doi.org/10.1016/j.ophtha.2020.06.018 First of two pivotal phase 3 trials supporting Durysta approval; defined the corneal endothelial risk with repeated implantation.
- Bacharach J, Tatham A, Ferguson G, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017–2033. https://doi.org/10.1007/s40265-021-01624-9 Companion pivotal trial to ARTEMIS 1 confirming non-inferiority to timolol and supporting long-term safety.
- Gedde SJ, Vinod K, Wright MM, et al; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2021;128(1):P71–P150. https://doi.org/10.1016/j.ophtha.2020.10.022 AAO flagship guideline positioning prostaglandin analogs as first-line pharmacotherapy for POAG; underpins current clinical practice.
- Gedde SJ, Lind JT, Wright MM, et al; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern®. Ophthalmology. 2021;128(1):P151–P192. https://doi.org/10.1016/j.ophtha.2020.10.023 Companion AAO document covering ocular hypertension management — relevant because Lumigan is indicated for this population.
- American Academy of Ophthalmology. Glaucoma Summary Benchmarks (2025 update). https://www.aao.org/education/summary-benchmark-detail/glaucoma-summary-benchmarks-2020 Practice benchmarks distilled from the AAO PPPs used to standardise glaucoma care; includes target IOP thresholds and monitoring frequency.
- Huang AS, Ngai P, Fuschetto Camacho G, et al. Bimatoprost Ophthalmic Solution. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK576421/ Peer-reviewed reference providing consolidated pharmacology and mechanism of action discussion for bimatoprost, including prostamide receptor biology.
- Taketani Y, Yamagishi R, Fujishiro T, et al. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1269–1276. https://doi.org/10.1167/iovs.13-12589 Mechanistic study linking FP receptor activation to inhibition of adipogenesis — the molecular basis for prostaglandin-associated periorbitopathy.
- Shirley M. Bimatoprost Implant: First Approval. Drugs Aging. 2020;37(6):457–462. https://doi.org/10.1007/s40266-020-00769-8 Peer-reviewed summary of the Durysta implant development programme, pharmacokinetic rationale, and initial safety profile.
- Medeiros FA, Sheybani A, Shah MM, et al. Single Administration of Intracameral Bimatoprost Implant 10 μg in Patients with Open-Angle Glaucoma or Ocular Hypertension. Ophthalmol Ther. 2022;11(4):1517–1537. https://doi.org/10.1007/s40123-022-00527-6 Phase 1/2 APOLLO trial demonstrating durable IOP lowering from a single 10 µg implant and defining the favourable safety profile supporting single-administration labelling.
- Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013;8(5):e61638. https://doi.org/10.1371/journal.pone.0061638 Characterises the full prostaglandin-associated periorbitopathy spectrum and frequency — supports counselling on long-term cosmetic risks.